In fact, while the inhibition of BRAF or of combined BRAF/MEK initially reduced the tumor progression in BRAFV600E mutant melanoma patients, the targeted therapy resistance emerged in most of them within 1 or 2 years, via several mechanisms. The gene discussed is MAP2K7; the disease is melanoma.